Dr. Charles Burger, MD
Pulmonology (Pulmonary Disease Physician)
- Medicare participating
At a glance
- Medical school
- Wake Forest University School of Medicine (1985)
- Years since graduation
- 41
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 114
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1985Medical school: Wake Forest University School of Medicine
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pulmonary Disease Physician primary
FL license ME57557
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Mayo Clinic Jacksonville, FL
Medical groups
- Mayo Clinic Jacksonville (1,615 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 114
- Services billed
- 158
- Patients’ average age
- 70
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 99 | 85 |
| Established patient office or other outpatient visit, 40-54 minutes | 75 | 63 |
| Test to examine how well the lungs exchange gases | 71 | 71 |
| Test to determine lung volumes using sensors | 67 | 67 |
| Test to measure expiratory airflow and volume | 55 | 51 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 42 | 42 |
| New patient office or other outpatient visit, 60-74 minutes | 40 | 40 |
| New patient office or other outpatient visit, 45-59 minutes | 35 | 35 |
| Test for exercise-induced heart and lung stress | 33 | 29 |
| Test for exercise-induced lung stress | 26 | 25 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Ambrisentan | 201 |
| Opsumit (macitentan) | 190 |
| Sildenafil Citrate Other prescribers in Jacksonville, FL | 160 |
| Tadalafil | 126 |
| Adempas (riociguat) | 125 |
| Spironolactone Other prescribers in Jacksonville, FL | 73 |
| Furosemide Other prescribers in Jacksonville, FL | 73 |
| Uptravi (selexipag) | 43 |
| Prednisone Other prescribers in Jacksonville, FL | 30 |
| Bumetanide Other prescribers in Jacksonville, FL | 28 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 7 companies reported 39 payments worth $23,922 in total to this clinician.
| Merck Sharp & Dohme LLC | $16,414 |
|---|---|
| Insmed, Inc. | $5,030 |
| Actelion Pharmaceuticals US, Inc. | $1,470 |
| United Therapeutics Corporation | $621 |
| Bayer HealthCare Pharmaceuticals Inc. | $200 |
| Chiesi USA, Inc. | $110 |
| Janssen Pharmaceuticals, Inc | $76.83 |
| Consulting Fee | $20,310 |
|---|---|
| Travel and Lodging | $1,818 |
| Food and Beverage | $1,794 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC Nov 24, 2025 | Consulting Fee | $10,240 |
| Insmed, Inc. Jun 22, 2025 | Consulting Fee | $5,030 |
| Merck Sharp & Dohme LLC Dec 10, 2025 | Consulting Fee | $3,840 |
| Actelion Pharmaceuticals US, Inc. Jun 16, 2025 | Consulting Fee OPSUMIT · Cardiology | $1,000 |
| Merck Sharp & Dohme LLC Nov 13, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Plano, TX · in-kind | $387 |
| Merck Sharp & Dohme LLC Dec 3, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Boston, MA · in-kind | $282 |
| Merck Sharp & Dohme LLC Nov 13, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Plano, TX · in-kind | $256 |
| Merck Sharp & Dohme LLC Nov 14, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Plano, TX · in-kind | $256 |
| Merck Sharp & Dohme LLC Nov 13, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Plano, TX · in-kind | $221 |
| Bayer HealthCare Pharmaceuticals Inc. Sep 30, 2025 | Consulting Fee Adempas · Cardio-pulmonary | $200 |
All 13 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC Dec 10, 2025 | Consulting Fee | $3,840 |
| Merck Sharp & Dohme LLC Dec 10, 2025 | Travel and Lodging travel to Boston, MA | $150 |
| Merck Sharp & Dohme LLC Dec 3, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Boston, MA · in-kind | $282 |
| Merck Sharp & Dohme LLC Nov 24, 2025 | Consulting Fee | $10,240 |
| Merck Sharp & Dohme LLC Nov 24, 2025 | Travel and Lodging travel to Dallas, TX | $150 |
| Merck Sharp & Dohme LLC Nov 14, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Plano, TX · in-kind | $256 |
| Merck Sharp & Dohme LLC Nov 13, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Plano, TX · in-kind | $387 |
| Merck Sharp & Dohme LLC Nov 13, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Plano, TX · in-kind | $256 |
| Merck Sharp & Dohme LLC Nov 13, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Plano, TX · in-kind | $221 |
| Merck Sharp & Dohme LLC Nov 13, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Plano, TX · in-kind | $116 |
| Bayer HealthCare Pharmaceuticals Inc. Sep 30, 2025 | Consulting Fee Adempas · Cardio-pulmonary | $200 |
| Insmed, Inc. Jun 22, 2025 | Consulting Fee | $5,030 |
| Actelion Pharmaceuticals US, Inc. Jun 16, 2025 | Consulting Fee OPSUMIT · Cardiology | $1,000 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 2 companies. The companies reported $808,730 in research payments for these studies, mostly to the institutions running them.
- A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Sotatercept When Added to Maximum Tolerated Background Therapy in Participants With Pulmonary Arterial Hypertension PAH World Health Organizati…
Merck Sharp & Dohme LLC - A Phase 2, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effects of Sotatercept versus Placebo for the Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension Cpc-PH due to Hea…
Merck Sharp & Dohme LLC - A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients
United Therapeutics Corporation · Completed · NCT03626688 - An Open-Label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arterial Hypertension PAH Therapy for the Treatment of PAH
Merck Sharp & Dohme LLC - An Open-label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arterial Hypertension PAH Therapy for the Treatment of PAH MK-7962-038
Merck Sharp & Dohme LLC - A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension
United Therapeutics Corporation · Enrolling by invitation · NCT03683186
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.